Trial Profile
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Betrixaban (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals
- 11 Apr 2023 Status changed from completed to discontinued. The Sponsor decided to stop developing betrixaban, leading to early study closure after completing Part 1 and before initiating Part 2
- 02 Oct 2020 Status changed from recruiting to completed.
- 22 Sep 2020 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database record.